World Mental Health Survey, Lebanon, 2002-2003 (ICPSR 39729)

Version Date: Jun 23, 2026

Cite this study |

Principal Investigator(s):
Elie G. Karam, Institute for Development, Research, Advocacy and Applied Care; Josleen Al Barathie, Institute for Development, Research, Advocacy and Applied Care; Hani Dimasi, Institute for Development, Research, Advocacy and Applied Care; John Fayyad, Institute for Development, Research, Advocacy and Applied Care; Aimee Nasser Karam, Institute for Development, Research, Advocacy and Applied Care; Georges E. Karam, Institute for Development, Research, Advocacy and Applied Care; Zeina Mneimneh, Institute for Development, Research, Advocacy and Applied Care

Series:

https://doi.org/10.3886/ICPSR39729.v1

Version V1

Slide tabs to view more

Summary

The World Mental Health (WMH) Survey Initiative was a coordinated series of general population surveys of mental, substance use, and behavioral disorders conducted in countries across all World Health Organization (WHO) regions. The approach taken by WMH was to conduct rigorous general population surveys in nationally representative samples in many countries throughout the world, to generate data from these surveys on the prevalence, severity, course, and treatment of mental disorders. Data were collected using the WHO Composite International Diagnostic Interview (CIDI) which uses both ICD-10 and DSM-III diagnostic criteria. This survey was conducted in Lebanon and utilized the Arabic version of the CIDI.

Citation

Karam, Elie G., Al Barathie, Josleen, Dimasi, Hani, Fayyad, John, Karam, Aimee Nasser, Karam, Georges E., and Mneimneh, Zeina. World Mental Health Survey, Lebanon, 2002-2003. Inter-university Consortium for Political and Social Research [distributor], 2026-06-23. https://doi.org/10.3886/ICPSR39729.v1

Export Citation:

  • RIS (generic format for RefWorks, EndNote, etc.)
  • EndNote

Funding

Ministry of Public Health (Lebanon), World Health Organization, Algorithm, AstraZeneca, Benta Lyon, Bella Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Novartis, Omnipharma, Pfizer Foundation, Droguerie Phenicia, Servier, Union Pharmaceutique d'Orient, United States Department of Health and Human Services. National Institutes of Health. National Institute of Mental Health (R01 MH070884), John D. and Catherine T. MacArthur Foundation, United States. Public Health Service (R13-MH066849; R01-MH069864; R01 DA016558), United States Department of Health and Human Services. National Institutes of Health. Fogarty International Center (R03-TW006481; R03 TW006481-01), Pan American Health Organization, Ortho-McNeil, Bristol-Myers Squibb Company, Janssen-Cilag, Roche

Subject Terms

Geographic Coverage

Smallest Geographic Unit

Country

Restrictions

This data collection may not be used for any purpose other than statistical reporting and analysis. Use of these data to learn the identity of any person or establishment is prohibited. To protect respondent privacy, the data file in this collection is restricted from general dissemination. To obtain this restricted file, researchers must agree to the terms and conditions of a Restricted Data Use Agreement.

Distributor(s)

Inter-university Consortium for Political and Social Research
Hide

Time Period(s)

2002 -- 2003

Data Collection Notes

  1. For additional information on the World Mental Health (WMH) Survey Initiative, please visit the World Mental Health Survey Initiative website.

  2. Supporting documentation to distinguish Part I and II of the survey was not included. Users can utilize crosstabs on the weight variables FINALP1WT and FINALP2WT to determine whether variables in Datasets 1 and 2 were derived from Part I or II of the survey.

    • If a participant without valid values for FINALP2WT responded to a variable, that variable is in Part I of the survey.
    • Variables that only have responses from participants with FINALP2WT valid values are in Part II of the survey.

  3. The Restricted-Use Raw Lebanon Data were provided without complete variable and value labels, but with a P.I. Questionnaire. This Raw dataset and the corresponding documents are released to provide supplemental information. The Raw dataset is released as Restricted-Use because it contains the original, more granular variables that were used to create the constructed variables in the Public-Use Cleaned Lebanon Data and the Restricted-Use Cleaned Lebanon data.

Hide

Study Purpose

The WMH Survey Initiative was designed to fill major gaps in global mental health data. Earlier estimates of the burden of mental and addictive disorders relied largely on literature reviews and isolated studies. WMH surveys provide nationally or regionally representative data to:

  • Estimate the prevalence and distribution of mental, substance use, and behavioral disorders
  • Identify risk and protective factors to inform prevention and intervention strategies
  • Describe patterns of service use, unmet need, and barriers to care
  • Improve estimates of the global burden of disease attributable to mental disorders for public health planning

Study Design

The survey was administered in two parts. Part I was administered to all respondents. Part II was administered to a probability sub-sample of respondents based on responses to the Part I questions. In addition, a probability subsample of other Part I respondents (i.e., those who did not meet criteria for any core disorder) was also selected to complete Part II, while interviews with the remaining non-cases were ended after the completion of the Part I questions.

Sample

3 design stages; (1) stratification by regions and ethnic composition of ED (units- census ED(960)); (2) household; (3) random adult.

Time Method

Cross-sectional

Universe

Arabic speaking Lebanese citizens aged 18 or older living in Lebanon residences, excluding Beirut; nationally representative.

Unit(s) of Observation

Individuals

Data Type(s)

Mode of Data Collection

Response Rates

The overall response rate was 70.00 percent.

Presence of Common Scales

Composite International Diagnostic Interview (CIDI) Version 3.0

Hide

Original Release Date

2026-06-23

Hide

Weight

The final analysis weight (FINALP1WT) for each respondent was computed as the product of three weight components: the selection weight factor for the respondent, the nonresponse weight adjustment factor for the respondent, and the post-stratification factor for the respondent. The final analysis weight (FINALP2WT) for each respondent administered Part II was computed similarly to FINALP1WT for that subsample of respondents. As a practical matter for analysts, the following decision rules should be applied when selecting the weight to use. When using only variables from Part I, the FINALP1WT weight variable should be used. For analyses with only Part II or a combination of Part I and Part II variables, the Part II weight or FINALP2WT should be used.

Hide

Notes